Hogan Lovells Team Advises Gilead Sciences in a License Agreement With Xencor, for Use of XmAb Antibody Technologies in Investigational Agents for HIV
January 15, 2020
January 15, 2020
NEW YORK, Jan. 15 -- Hogan Lovells, a multinational law firm, issued the following news release:
International law firm Hogan Lovells has advised Gilead Sciences, Inc.in entering into a technology license agreement with Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases.
The agreement will grand Gilead Sciences access to Xencor's Xtend(TM) exte . . .
International law firm Hogan Lovells has advised Gilead Sciences, Inc.in entering into a technology license agreement with Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases.
The agreement will grand Gilead Sciences access to Xencor's Xtend(TM) exte . . .